# Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

> **NCT01276769** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 80 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Paclitaxel plus carboplatin
- **DRUG:** Paclitaxel and epirubicin

## Key facts

- **NCT ID:** NCT01276769
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-01
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2011-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276769, "Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01276769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*